Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.41 |
| ▸ | ECE1 | P42892 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638079 | 0.92 | ECE1 (0.44) | NOD1BMP1ECE1 | |
| SCHEMBL30578645 | 0.89 | FOLH1 (0.51) | NOD1FOLH1NAALAD2RIMKLA | |
| SCHEMBL29488080 | 0.89 | FOLH1 (0.51) | NOD1FOLH1NAALAD2RIMKLA | |
| SCHEMBL7300355 | 0.89 | FOLH1 (0.46) | BMP1KMT2AFOLH1 | |
| SCHEMBL7300344 | 0.89 | FOLH1 (0.46) | BMP1KMT2AFOLH1 | |
| SCHEMBL9073100 | 0.88 | BMP1 (0.45) | NOD1BMP1KMT2AFOLH1ECE1 | |
| SCHEMBL19177556 | 0.86 | KMT2A (0.43) | NOD1BMP1KMT2AFOLH1ECE1 | |
| SCHEMBL29373145 | 0.86 | SLC15A2 (0.49) | NOD1FOLH1 | |
| SCHEMBL31670609 | 0.86 | BMP1 (0.41) | NOD1BMP1 | |
| SCHEMBL268801 | 0.85 | KMT2A (0.49) | NOD1KMT2AFOLH1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0087750-B2 | Amino acid preparations containing glutaminic residues | KABI PHARMACIA GMBH (DE) | 1994-04-27 | — | — | EP | claimed |
| CN-121449690-A | GALR2 selective polypeptide agonist and preparation method and application thereof | 宁夏医科大学 | 2026-02-03 | — | — | CN | disclosed |
| US-20240400635-A1 | FUSION COMPOUNDS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2024-12-05 | — | — | US | disclosed |
| WO-2022092284-A1 | COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER | 日産化学株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022065433-A1 | COSMETIC FOR HAIR | 日産化学株式会社 | 2022-03-31 | — | — | WO | disclosed |
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2-SCIENCE APS (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-2036567-A2 | Modulation of the P2Y2 receptor pathway | P2-Science APS (DK) | 2009-03-18 | — | — | EP | disclosed |
| EP-1959968-A2 | MODULATION OF THE P2Y2 RECEPTOR PATHWAY | P2-Science APS (DK) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065437-A2 | MODULATION OF THE P2Y2 RECEPTOR PATHWAY | P2-SCIENCE APS (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-7056889-B2 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK, WORLDWIDE, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| CN-1720061-A | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY CLARK CO (US) | 2006-01-11 | — | — | CN | disclosed |
| EP-0087750-B2 | Amino acid preparations containing glutaminic residues | KABI PHARMACIA GMBH (DE) | 1994-04-27 | — | — | EP | disclosed |
| EP-0087750-B1 | AMINO ACID PREPARATIONS CONTAINING GLUTAMINIC RESIDUES | Kabi Pharmacia GmbH (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0087751-B1 | WATER-SOLUBLE PEPTIDES FROM VERY POORLY SOLUBLE AMINO ACIDS | PFRIMMER KABI GMBH & CO. KG (DE) | 1985-05-29 | — | — | EP | disclosed |
| EP-0087751-A2 | Water-soluble peptides from very poorly soluble amino acids | PFRIMMER KABI GMBH & CO. KG (DE) | 1983-09-07 | — | — | EP | disclosed |
| EP-0087750-A2 | Amino acid preparations containing glutaminic residues | Kabi Pharmacia GmbH (DE) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2RY2, P2RY1, P2RY11 | NOD1 656/4885BMP1 4160/4885KMT2A 3382/4885 |
| US-20240400635-A1 | FUSION COMPOUNDS AND USES THEREOF | GLP1R, FGF1, FGFR1 | NOD1 795/4885BMP1 29/4885KMT2A 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.